Clinical Trial Update: Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating nivolumab with tumor-infiltrating lymphocytes in advanced non-small cell lung cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinomas
• Adenosquamous Carcinoma
• Non Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2022-04-13